Cover Image

Therapeutic inhibition of RBM20 improves diastolic function in a murine heart failure model and human engineered heart tissue

Heart failure with preserved ejection fraction (HFpEF) is prevalent and deadly, but so far, there is no targeted therapy. A main contributor to the disease is impaired ventricular filling, which we improved with antisense oligonucleotides (ASOs) targeting the cardiac splice factor RBM20. In adult mi...

Full description

Saved in:
Bibliographic Details
Main Authors: Radke, Michael (Author) , Badillo-Lisakowski, Victor (Author) , Britto-Borges, Thiago (Author) , Kubli, Dieter A. (Author) , Jüttner, René (Author) , Parakkat, Pragati (Author) , Carballo, Jacobo Lopez (Author) , Hüttemeister, Judith (Author) , Liss, Martin (Author) , Hansen, Arne (Author) , Dieterich, Christoph (Author) , Mullick, Adam E. (Author) , Gotthardt, Michael (Author)
Format: Article (Journal)
Language:English
Published: 1 Dec 2021
In: Science translational medicine
Year: 2021, Volume: 13, Issue: 622, Pages: 1-11
ISSN:1946-6242
DOI:10.1126/scitranslmed.abe8952
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1126/scitranslmed.abe8952
Verlag, lizenzpflichtig, Volltext: https://www.science.org/doi/abs/10.1126/scitranslmed.abe8952
Get full text
Author Notes:Michael H. Radke, Victor Badillo-Lisakowski, Thiago Britto-Borges, Dieter A. Kubli, René Jüttner, Pragati Parakkat, Jacobo Lopez Carballo, Judith Hüttemeister, Martin Liss, Arne Hansen, Christoph Dieterich, Adam E. Mullick, Michael Gotthardt
Description
Summary:Heart failure with preserved ejection fraction (HFpEF) is prevalent and deadly, but so far, there is no targeted therapy. A main contributor to the disease is impaired ventricular filling, which we improved with antisense oligonucleotides (ASOs) targeting the cardiac splice factor RBM20. In adult mice with increased wall stiffness, weekly application of ASOs over 2 months increased expression of compliant titin isoforms and improved cardiac function as determined by echocardiography and conductance catheter. RNA sequencing confirmed RBM20-dependent isoform changes and served as a sensitive indicator of potential side effects, largely limited to genes related to the immune response. We validated our approach in human engineered heart tissue, showing down-regulation of RBM20 to less than 50% within 3 weeks of treatment with ASOs, resulting in adapted relaxation kinetics in the absence of cardiac pathology. Our data suggest anti-RBM20 ASOs as powerful cardiac splicing regulators for the causal treatment of human HFpEF.
Item Description:Gesehen am 19.01.2022
Physical Description:Online Resource
ISSN:1946-6242
DOI:10.1126/scitranslmed.abe8952

Similar Items